Parkinson’s Disease Patients at Higher Risk for Melanoma
By LabMedica International staff writers Posted on 24 Jul 2017 |
Study finds that people with Parkinson’s disease have a much higher risk of the skin cancer melanoma, and vice versa. Physicians treating patients with one disease should be vigilant for signs of the other in order to achieve early diagnosis and treatment, and patients should be educated about the risk of developing the other illness.
Medical experts have speculated about causes underlying the connection between Parkinson’s and melanoma for decades, with varying conclusions. Several studies have suggested levodopa, a drug for Parkinson’s, may be implicated in malignant melanoma, but others have found an association between the two diseases regardless of levodopa treatment.
According to a Mayo Clinic (Rochester, MN, USA) study led by Jose Pulido, MD: patients with Parkinson’s were roughly 4 times likelier to have had a history of melanoma than those without Parkinson’s, and patients with melanoma had a 4-fold higher risk of developing Parkinson’s. The study team used the Rochester Epidemiology Project medical records database to identify all neurologist-confirmed Parkinson’s cases from January 1976 through December 2013 among Olmsted County (MN, USA) residents. They examined the prevalence of melanoma in those 974 patients compared with 2,922 residents without Parkinson’s. They also identified 1,544 cases of melanoma over that period and determined the 35-year risk of Parkinson’s in those patients compared with the risk in people without melanoma.
The results support an association between Parkinson’s disease and melanoma, but argue against levodopa as the cause. It is likelier that common abnormalities underlie both conditions in patients who have both, but more research is needed to confirm that and refine screening recommendations.
“Future research should focus on identifying common genes, immune responses, and environmental exposures that may link these two diseases,” said first author Lauren Dalvin, MD, a Mayo Foundation scholar, “If we can pinpoint the cause of the association between Parkinson’s disease and melanoma, we will be better able to counsel patients and families about their risk of developing one disease in the setting of the other."
The study, by Dalvin LA et al, was published July 2017 in the journal Mayo Clinic Proceedings.
Related Links:
Mayo Clinic
Medical experts have speculated about causes underlying the connection between Parkinson’s and melanoma for decades, with varying conclusions. Several studies have suggested levodopa, a drug for Parkinson’s, may be implicated in malignant melanoma, but others have found an association between the two diseases regardless of levodopa treatment.
According to a Mayo Clinic (Rochester, MN, USA) study led by Jose Pulido, MD: patients with Parkinson’s were roughly 4 times likelier to have had a history of melanoma than those without Parkinson’s, and patients with melanoma had a 4-fold higher risk of developing Parkinson’s. The study team used the Rochester Epidemiology Project medical records database to identify all neurologist-confirmed Parkinson’s cases from January 1976 through December 2013 among Olmsted County (MN, USA) residents. They examined the prevalence of melanoma in those 974 patients compared with 2,922 residents without Parkinson’s. They also identified 1,544 cases of melanoma over that period and determined the 35-year risk of Parkinson’s in those patients compared with the risk in people without melanoma.
The results support an association between Parkinson’s disease and melanoma, but argue against levodopa as the cause. It is likelier that common abnormalities underlie both conditions in patients who have both, but more research is needed to confirm that and refine screening recommendations.
“Future research should focus on identifying common genes, immune responses, and environmental exposures that may link these two diseases,” said first author Lauren Dalvin, MD, a Mayo Foundation scholar, “If we can pinpoint the cause of the association between Parkinson’s disease and melanoma, we will be better able to counsel patients and families about their risk of developing one disease in the setting of the other."
The study, by Dalvin LA et al, was published July 2017 in the journal Mayo Clinic Proceedings.
Related Links:
Mayo Clinic
Latest Molecular Diagnostics News
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer